Department of Psychiatry and Psychotherapy, Biological Psychiatry Division, Medical University Innsbruck, Innsbruck, Austria.
Int Clin Psychopharmacol. 2013 Jul;28(4):214-6. doi: 10.1097/YIC.0b013e328361e145.
We report on the successful use of a combined psychopharmacological treatment in a patient with Huntington's disease, at age 39, suffering from severe psychotic and behavioral symptoms. He presented with a schizophreniform psychosis accompanied by aggressive behavior leading to admission to the locked ward of our hospital. After unsatisfactory control of the psychiatric symptoms with olanzapine, risperidone, and amisulpride, we introduced aripiprazole. This did not affect the psychotic symptoms; however, led to an improvement in aggressive behavior, motivation, and even chorea. Accordingly, we choose not to switch medication but to add clozapine. Nevertheless, his delusions improved slightly, and further add-on treatment with reboxetine brought a further beneficial effect on motivation and activities of daily living. As chorea was not disabling in our patient, tetrabenazine has not yet been tried. Treatment was safe without any relevant side effects.
我们报告了一例成功的联合精神药理学治疗病例,患者为 39 岁的亨廷顿病患者,表现为严重的精神病和行为症状。他表现为伴有攻击行为的精神分裂样精神病,导致被收入我院的封闭病房。奥氮平、利培酮和氨磺必利对精神病症状控制不佳后,我们引入阿立哌唑。这并未影响精神病症状,但改善了攻击行为、动机,甚至舞蹈病。因此,我们选择不换药,而是加用氯氮平。尽管如此,他的妄想略有改善,进一步添加文拉法辛对动机和日常生活活动也有有益影响。由于我们的患者舞蹈病并不致残,尚未尝试使用丁苯那嗪。治疗是安全的,没有任何相关的副作用。